Drug Cuts Lung Cancer Return Risk by 83% in UCLA Study

UCLA researchers discovered a targeted therapy drug that dramatically reduces the risk of lung cancer returning in patients with a rare genetic subtype.

After two years, 92% of patients receiving the treatment remained cancer-free, compared to just 61% who received a placebo.